Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid

Green, BD; Gault, Victor; Flatt, Peter R.; Harriott, Patrick; Greer, Brett; O’Harte, Finbarr

doi:10.1016/j.abb.2004.05.005

Cited by 48 publications

(23 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The subsequent influx of Ca 2+ then activates Ca 2+ -sensitive enzymes such as phospholipase A2 (PLA2), phospholipase C, adenylate cyclase that forms cAMP and protein kinase A (PKA), and activates the mechanisms of vesicle exocytosis to release insulin into the extracellular space (Leech and Habener, 1997;Suzuki et al, 1997;Green et al, 2004;Kim et al, 2005a,b). The same biochemical mechanisms that control the release of neurotransmitters into the synaptic cleft via vesicles are found in neurons (Winder and Conn, 1993;Okamoto et al, 1994;Wheeler et al, 1994).…”

Section: The Gip Receptor Signaling Pathwaymentioning

confidence: 99%

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

Xue

et al. 2016

Reviews in the Neurosciences

View full text Add to dashboard Cite

AbstractGlucose-dependent insulinotropic polypeptide (GIP) is a member of the incretin hormones and growth factors. Neurons express the GIP receptor, and GIP and its agonists can pass through the blood brain barrier and show remarkable neuroprotective effects by protecting synapse function and numbers, promoting neuronal proliferation, reducing amyloid plaques in the cortex and reducing the chronic inflammation response of the nervous system. Long-acting analogues of GIP that are protease resistant had been developed as a treatment for type 2 diabetes. It has been found that such GIP analogues show good protective effects in animal models of Alzheimer’s disease. Novel dual agonist peptides that activate the GIP receptor and another incretin receptor, glucagon-like peptide -1 (GLP-1), are under development that show superior effects in diabetic patients compared to single GLP-1 agonists. The dual agonists also show great promise in treating neurodegenerative disorders, and there are currently several clinical trials ongoing, testing GLP-1 mimetics in people with Alzheimer’s or Parkinson’s disease.

show abstract

Section: The Gip Receptor Signaling Pathwaymentioning

confidence: 99%

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

Xue

et al. 2016

Reviews in the Neurosciences

View full text Add to dashboard Cite

show abstract

“…15 Considering the diversity of these endogenous peptides, we can envision a therapeutic approach based on a cocktail of peptides, which target different aspects containing multiple cysteines can be difficult to synthesize and are often unstable due to their ease of oxidation, thus they are replaced by other amino acids such as serine or by non-natural amino acids that are structurally similar but more stable such as L-α-amino-n-butyric acid. [19][20][21][22][23][24][25] In this study we present the biological activity of a biomimetic peptide modified from an endogenous sequence derived from the α5 fibril of collagen IV, whose anti-angiogenic activity was previously demonstrated in MDA-MB-231 ER/PR/HER2 triple negative breast cancer xenograft model. 26 We generated a second generation peptide that is more stable and maintains its biological activity thus creating a potential drug candidate for translation to clinical applications.…”

Section: Development Of a Biomimetic Peptide Derived From Collagen IVmentioning

confidence: 99%

Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer

Roşca¹,

Koskimaki

Pandey

et al. 2011

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…GLP-1R is a member of a different class of receptors compared with insulin receptor (IR). The activation of GLP-1R activates adenylyl cyclase and increases cAMP levels (Green et al, 2004), which stimulates PKA and enhances the transcription of IR substrate (IRS) 2 (Broca et al, 2009). By this pathway, it can link with the signaling pathway of IR.…”

Section: Inhibition Of τ Phosphorylation By Geniposidementioning

confidence: 99%

Neuroprotective effects of geniposide on Alzheimer’s disease pathology

Liu

Hölscher³

et al. 2015

Reviews in the Neurosciences

View full text Add to dashboard Cite

AbstractA growing body of evidence has linked two of the most common aged-related diseases: type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD). It has led to the notion that drugs developed for the treatment of T2DM may be beneficial in modifying the pathophysiology of AD. As a receptor agonist of glucagon-like peptide-1 (GLP-1R), which is a newer drug class to treat T2DM, geniposide shows clear effects in inhibiting pathological processes underlying AD, such as promoting neurite outgrowth. In the present article, we review the possible molecular mechanisms of geniposide to protect the brain from pathologic damages underlying AD: reducing amyloid plaques, inhibiting τ phosphorylation, preventing memory impairment and loss of synapses, reducing oxidative stress and the chronic inflammatory response, and promoting neurite outgrowth via the GLP-1R signaling pathway. In summary, the Chinese herb geniposide shows great promise as a novel treatment for AD.

show abstract

Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and in vivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid

Cited by 48 publications

References 49 publications

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer

Neuroprotective effects of geniposide on Alzheimer’s disease pathology

Contact Info

Product

Resources

About